Lipoprotein(a) and the Risk for Coronary Heart Disease and Ischemic Stroke Events Among Black and White Adults With Cardiovascular Disease
Lisandro D. Colantonio,Vera Bittner,Monika M. Safford,Santica Marcovina,Todd M. Brown,Elizabeth A. Jackson,Mei Li,J. Antonio G. López,Keri L. Monda,Timothy B. Plante,Shia T. Kent,Paul Muntner,Robert S. Rosenson
DOI: https://doi.org/10.1161/JAHA.121.025397
2022-05-29
Abstract:Background It is unclear whether lipoprotein(a) is associated with coronary heart disease (CHD) and ischemic stroke events in White and Black adults with atherosclerotic cardiovascular disease (ASCVD). Methods and Results We conducted a case‐cohort analysis, including Black and White REGARDS (Reasons for Geographic and Racial Differences in Stroke) study participants ≥45 years of age with prevalent ASCVD (ie, CHD or stroke) at baseline between 2003 and 2007. Baseline lipoprotein(a) molar concentration was measured in participants with ASCVD who experienced a CHD event by December 2017 (n=1166) or an ischemic stroke by September 2019 (n=492) and in a random subcohort of participants with prevalent ASCVD (n=1948). The hazard ratio (HR) for CHD events per 1 SD (1.5 units) higher log‐transformed lipoprotein(a) was 1.26 (95% CI, 1.02–1.56) among Black participants and 1.16 (95% CI, 1.02–1.31) among White participants ( P value comparing HRs, 0.485). The HR for CHD events per 1 SD higher log‐lipoprotein(a) within subgroups with hs‐CRP (high‐sensitivity C‐reactive protein) ≥2 and <2 mg/L was 1.31 (95% CI, 0.99–1.73) and 1.23 (95% CI, 0.85–1.80), respectively ( P value comparing HRs, 0.836), among Black participants, and 1.07 (95% CI, 0.91–1.27) and 1.36 (95% CI, 1.10–1.70), respectively ( P value comparing HRs, 0.088), among White participants. There was no evidence that the association between lipoprotein(a) and CHD events differed by statin use. There was no evidence of an association between lipoprotein(a) and ischemic stroke events among Black or White participants. Conclusions Higher lipoprotein(a) levels were associated with an increased risk for CHD events in Black and White adults with ASCVD. Nonstandard Abbreviations and Acronyms ApoB apolipoprotein B REGARDS Reasons for Geographic and Racial Differences in Stroke Clinical Perspective What Is New? Black and White US adults with a history of atherosclerotic cardiovascular disease who had higher lipoprotein(a) levels had an increased risk for future coronary heart disease events. The association between lipoprotein(a) and the risk for future coronary heart disease events did not differ by race, statin use, or high‐sensitivity C‐reactive protein levels. There was no association between lipoprotein(a) levels and the risk for ischemic stroke events among Black and White US adults with a history of atherosclerotic cardiovascular disease. What Are the Clinical Implications? Elevated lipoprotein(a) levels can be used to identify Black and White adults with a history of atherosclerotic cardiovascular disease who have an increased risk for future coronary heart disease events and may benefit from more intensive risk reduction interventions, including those taking a statin. Elevated lipoprotein(a) levels have been associated with an increased risk for incident coronary heart disease (CHD) 1 , 2 , 3 and ischemic stroke 1 , 4 in observational studies. Mendelian randomization analyses also suggest that the association of lipoprotein(a) with incident CHD and ischemic stroke may be causal. 5 , 6 Adults with a history of atherosclerotic cardiovascular disease (ASCVD) have a high risk for CHD and ischemic stroke events. 7 , 8 However, there are limited data about whether elevated lipoprotein(a) levels confer an increased risk for CHD and ischemic stroke events in individuals with ASCVD, particularly among Black adults, a population with higher lipoprotein(a) levels versus other racial groups. 9 , 10 , 11 , 12 , 13 , 14 If elevated lipoprotein(a) levels are associated with an increased risk for CHD and ischemic stroke events among Black and White adults with ASCVD, this would support the use of lipoprotein(a) for directing more intensive risk‐reduction interventions in this population. The goal of the current study was to determine the risk for CHD and ischemic stroke events associated with lipoprotein(a) levels among Black and White US adults with ASCVD, defined by a history -Abstract Truncated-